---
document_datetime: 2025-11-05 18:09:14
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-viatris-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-viatris-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7769766
conversion_datetime: 2025-12-31 03:12:36.66813
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pregabalin Viatris Pharma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 05/11/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000290223   | PL   |
|---------------------|------|

<div style=\"page-break-after: always\"></div>

|                                  | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.1 Solid, semi-solid and non-sterile liquid pharmaceutical forms - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.e Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for nonsterile   |            |    |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----|
| Article 61(3) / EMA/N/0000296185 | - Notification acc. Article 61(3) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/09/2025 | PL |

<div style=\"page-break-after: always\"></div>

|                                                         | Update of the package leaflet with revised contact details of local representative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IA / EMA/VR/0000285678                   | B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.2 New certificate for a starting material/reagent/ intermediate/or excipient from a new or an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted | 06/08/2025 | N/A        |                        |
| Marketing Authorisation Transfer - H / EMA/T/0000267061 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Upjohn EESV to Viatris Healthcare Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/05/2025 | 12/06/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000262282   | This was an application for a group of variations. B.II.a.1 Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - B.II.a.1.a Changes in imprints, bossing or other markings - Accepted A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted   | 07/04/2025   | N/A   | SmPC, Labelling and PL   |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------|
| Variation type IA_IN / EMA/VR/0000242692   | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted                                                                                                                      | 18/02/2025   | N/A   | Annex II and PL          |